Ayu Asakage

Dr. Ayu Asakage

Yokohama City Minato Red Cross Hospital
orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
21 December 2020 in Expert Opinion on Investigational Drugs
Verified
Journal Article
Closed access
BDBenjamin Deniau
Benjamin Deniau
KTKoji Takagi
Koji Takagi
AAAyu Asakage
Ayu Asakage
AMAlexandre Mebazaa
Alexandre Mebazaa
Sepsis is a major health problem with a high incidence and mortality. ADM, a free-circulating peptide mainly expressed and secreted by vascular endothelial cells, shows vasodilatory properties and ...

8 May 2023 in Current Heart Failure Reports
Verified
Journal Article
Closed access
PDF file
AAAyu Asakage
Ayu Asakage
JBJosefine Bækgaard
Josefine Bækgaard
AMAlexandre Mebazaa
Alexandre Mebazaa
BDBenjamin Deniau
Benjamin Deniau

29 September 2021 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
KTKoji Takagi
Koji Takagi
Bruno LévyBruno Lévy
Bruno Lévy
AKAntoine Kimmoun
Antoine Kimmoun
ÒMÒscar Miró
Òscar Miró
KDKévin Duarte
Kévin Duarte
AMAlexandre Mebazaa
Alexandre Mebazaa
Aims: Bioactive adrenomedullin (bio-ADM) was recently shown to be a prognostic marker in patients with acute circulatory failure. We investigate the association of bio-ADM with organ injury, functional impairment, and survival in cardiogenic shock (CS). Methods: OptimaCC was a multicenter and randomized trial in 57 patients with CS. In this post-hoc analysis, the primary endpoint was to assess the association between bio-ADM and 30-day all-cause mortality. Secondary endpoints included adverse events and parameters of organ injury or functional impairment. Results: Bio-ADM values were higher in 30-day non-survivors than 30-day survivors at inclusion (median (interquartile range) 67.0 (54.6–142.9) pg/mL vs. 38.7 (23.8–63.6) pg/mL, p = 0.010), at 24 h (p = 0.012), and up to 48 h (p = 0.027). Using a bio-ADM cutoff of 53.8 pg/mL, patients with increased bio-ADM had a HR of 3.90 (95% confidence interval 1.43–10.68, p = 0.008) for 30-day all-cause mortality, and similar results were observed even after adjustment for severity scores. Patients with the occurrence of refractory CS had higher bio-ADM value at inclusion (90.7 (59.9–147.7) pg/mL vs. 40.7 (23.0–64.7) pg/mL p = 0.005). Bio-ADM values at inclusion were correlated with pulmonary vascular resistance index, estimated glomerular filtration rate, and N-terminal pro-B-type natriuretic peptide (r = 0.49, r = –0.47, and r = 0.64, respectively; p < 0.001). Conclusions: In CS patients, the values of bio-ADM are associated with some parameters of organ injury and functional impairment and are prognostic for the occurrence of refractory CS and 30-day mortality.

26 September 2023 in Annals of Laboratory Medicine
Verified
Journal Article
Open access
PDF file
AAAyu Asakage
Ayu Asakage
SIShiro Ishihara
Shiro Ishihara
LBLouis Boutin
Louis Boutin
FDFrançois Dépret
François Dépret
TSTakeshi Sugaya
Takeshi Sugaya
BDBenjamin Deniau
Benjamin Deniau
Ayu Asakage, M.D., Shiro Ishihara, M.D., Louis Boutin, M.D., François Dépret, Ph.D., Takeshi Sugaya, Ph.D., Naoki Sato, Ph.D., Etienne Gayat, Ph.D., Alexandre Mebazaa, Ph.D., and Benjamin Deniau, Ph.D.. Ann Lab Med 2024;44:144-54. https://doi.org/10.3343/alm.2023.0083

16 October 2021 in Clinical Case Reports
Verified
Journal Article
Open access
PDF file
AAAyu Asakage
Ayu Asakage
MFMichiko Fujisawa
Michiko Fujisawa
TTTetsuhiro Takei
Tetsuhiro Takei
JKJiro Kumagai
Jiro Kumagai
Fat globule detection in the blood in fat embolism syndrome (FES) diagnosis remains controversial. This case illustrates two life‐threatening, possibly FES‐related, episodes with dramatic increases in blood fat globule level. Future studies should aim at evaluating the significance of the quantitative changes in blood fat levels in diagnosing FES.

27 November 2025 in Annals of Laboratory Medicine
Verified
Journal Article
Open access
PDF file
JBJolie Bruno
Jolie Bruno
ADAziz Daghmouri
Aziz Daghmouri
AAAyu Asakage
Ayu Asakage
CCCamille Chenevier-Gobeaux
Camille Chenevier-Gobeaux
KČKamilė Čerlinskaitė-Bajorė
Kamilė Čerlinskaitė-Bajorė
SIShiro Ishihara
Shiro Ishihara
Jolie Bruno, M.D., Aziz Daghmouri, M.D., Ayu Asakage, M.D., Camille Gobeaux, M.D., Kamilė Čerlinskaitė-Bajorė, M.D., Jelena Čelutkienė, M.D., Ph.D., Naoki Sato, M.D., Ph.D., Koji Takagi, M.D., Alexandre Mebazaa, M.D., Ph.D., Benjamin Deniau, M.D., Ph.D., and Shiro Ishihara, M.D., Ph.D.. Ann Lab Med -0001;0:. https://doi.org/10.3343/alm.2025.0232